The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12607000002482
Ethics application status
Not yet submitted
Date submitted
20/12/2006
Date registered
2/01/2007
Date last updated
2/01/2007
Type of registration
Prospectively registered

Titles & IDs
Public title
A Phase 3 Study of Abatacept in Patients With Active Crohn's Disease
Scientific title
Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With Abatacept in Subjects With Active Crohn's Disease (CD) Who Have Had an Inadequate Clinical Response and/or Intolerance to Medical Therapy
Secondary ID [1] 324 0
Bristol Myers Squibb (BMS): IM101-084
Universal Trial Number (UTN)
Trial acronym
IM101-084
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Crohns Disease 1505 0
Condition category
Condition code
Oral and Gastrointestinal 1603 1603 0 0
Crohn's disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Drug: Intravenous Abatacept 10mg/kg once a fortnight for the first month and then once a month from then on. Some subjects will recieve 30mg/kg for the first two doses.
Participants will be randsomised to be dosed with either Abatacept or placebo for the first 12 weeks. All participants who respond to treatment as per the protocol definition will then be randomised again to either placebo or abatacept for 12 months of treatment. All non responders will be offered open label abtacept for 1 year.
All subjects who disease is not controlled will be considered for either discontinuation or open label treatment if not already being dosed with this.
Intervention code [1] 1515 0
Treatment: Drugs
Comparator / control treatment
First stage: Placebo 12 weeks. Second stage: Placebo 12 months.
Control group
Placebo

Outcomes
Primary outcome [1] 2212 0
Reduction in Crohn's Disease Activity Index to meet clinical response criteria
Timepoint [1] 2212 0
At 8 weeks and 12 weeks during induction and at 12 months during maintenance
Secondary outcome [1] 3856 0
Reduction in Crohn's Disease Activity Index to meet clinical remission criteria.
Timepoint [1] 3856 0
At 8 weeks and 12 weeks during induction and at 12 months during maintenance.

Eligibility
Key inclusion criteria
Have had Crohn's Disease for at least 3 months *moderate to severely active Crohn's Disease *have had an inadequate response or intolerance to other Crohn's Disease treatments.
Minimum age
18 Years
Maximum age
Not stated
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Women of child bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 10 weeks after the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Treatment allocated through central randomisation system by phone and fax
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Stratified allocation. Based on previous response to anti Tumor Necrosis Factor (TNF) therapy.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Cross over dependant on response to therapy. All persons involved in the study except the safety monitoring board and the data analyst are blinded to allocation
Phase
Phase 3
Type of endpoint(s)
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 1747 0
Commercial sector/Industry
Name [1] 1747 0
Bristol-Myers Squibb
Address [1] 1747 0
Country [1] 1747 0
Primary sponsor type
Commercial sector/Industry
Name
Bristol-Myers Squibb
Address
Country
United States of America
Secondary sponsor category [1] 1544 0
None
Name [1] 1544 0
n/a
Address [1] 1544 0
Country [1] 1544 0

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 3226 0
Flinders Medical Centre
Ethics committee address [1] 3226 0
Ethics committee country [1] 3226 0
Australia
Date submitted for ethics approval [1] 3226 0
Approval date [1] 3226 0
Ethics approval number [1] 3226 0
Ethics committee name [2] 3227 0
St Vincents
Ethics committee address [2] 3227 0
Ethics committee country [2] 3227 0
Australia
Date submitted for ethics approval [2] 3227 0
Approval date [2] 3227 0
Ethics approval number [2] 3227 0
Ethics committee name [3] 3228 0
Mater Adult Hospital
Ethics committee address [3] 3228 0
Ethics committee country [3] 3228 0
Australia
Date submitted for ethics approval [3] 3228 0
Approval date [3] 3228 0
Ethics approval number [3] 3228 0
Ethics committee name [4] 3229 0
Box Hill Hospital
Ethics committee address [4] 3229 0
Ethics committee country [4] 3229 0
Australia
Date submitted for ethics approval [4] 3229 0
Approval date [4] 3229 0
Ethics approval number [4] 3229 0
Ethics committee name [5] 3230 0
Ballarat Base Hospital
Ethics committee address [5] 3230 0
Ethics committee country [5] 3230 0
Australia
Date submitted for ethics approval [5] 3230 0
Approval date [5] 3230 0
Ethics approval number [5] 3230 0
Ethics committee name [6] 3231 0
Fremantle Hospital
Ethics committee address [6] 3231 0
Ethics committee country [6] 3231 0
Australia
Date submitted for ethics approval [6] 3231 0
Approval date [6] 3231 0
Ethics approval number [6] 3231 0
Ethics committee name [7] 3232 0
Launceston General Hospital
Ethics committee address [7] 3232 0
Ethics committee country [7] 3232 0
Australia
Date submitted for ethics approval [7] 3232 0
Approval date [7] 3232 0
Ethics approval number [7] 3232 0
Ethics committee name [8] 3233 0
The Canberra hospital
Ethics committee address [8] 3233 0
Ethics committee country [8] 3233 0
Australia
Date submitted for ethics approval [8] 3233 0
Approval date [8] 3233 0
Ethics approval number [8] 3233 0
Ethics committee name [9] 3234 0
Royal Brisbane Hospital
Ethics committee address [9] 3234 0
Ethics committee country [9] 3234 0
Australia
Date submitted for ethics approval [9] 3234 0
Approval date [9] 3234 0
Ethics approval number [9] 3234 0
Ethics committee name [10] 3235 0
Royal Prince Alfred Hospital
Ethics committee address [10] 3235 0
Ethics committee country [10] 3235 0
Australia
Date submitted for ethics approval [10] 3235 0
Approval date [10] 3235 0
Ethics approval number [10] 3235 0

Summary
Brief summary
The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active Crohn's Disease in patients who have not had an adequate response to other therapies. The safety of this treatment will also be studied.
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 27449 0
Address 27449 0
Country 27449 0
Phone 27449 0
Fax 27449 0
Email 27449 0
Contact person for public queries
Name 10704 0
Dr Miles Sparrow
Address 10704 0
Gastroenterology Department
8th Floor
Eastern Health
Clive Ward Building
16 Arnold Street
Box Hill VIC 3128
Country 10704 0
Australia
Phone 10704 0
+61 3 98950369
Fax 10704 0
+61 3 98950353
Email 10704 0
Miles.sparrow@med.monash.edu.au.
Contact person for scientific queries
Name 1632 0
Dr Miles Sparrow
Address 1632 0
Gastroenterology Department
8th Floor
Eastern Health
Clive Ward Building
16 Arnold Street
Box Hill VIC 3128
Country 1632 0
Australia
Phone 1632 0
+61 3 98950369
Fax 1632 0
+61 3 98950353
Email 1632 0
Miles.sparrow@med.monash.edu.au.

No information has been provided regarding IPD availability
Summary results
No Results